GEN-MKT-18-7897-A
Feb 22, 2019 | Blogs, Software, Technology | 0 comments
At SCIEX we are committed to providing you with the most up-to-date tools and technologies to meet the evolving needs of the laboratory. As part of that commitment, we were introducing our software product roadmap towards Windows 10 compatibility back in 2017. Many of you are making long-term investments in SCIEX technologies, and we recognize how important it is for you to have visibility of new features coming down the road. As of February 2019, we can proudly announce that our complete suite of software solutions supports the Microsoft Windows 10 operating system (OS).
Our internal roadmap is a living document – it changes weekly to adapt quickly, respond to demand, capture opportunities, and optimize resources. While this roadmap was subject to change and we were not able to provide exact estimates or timelines on feature releases we hope it helped provide some insight into when individual SCIEX applications were made available on Windows 10.
Future-Proof Your System by Moving to Windows 10Presumably, you are aware that as of January 14, 2020, Microsoft will no longer support the Windows 7 OS. Therefore, your organization may already have started or completed the migration process to Windows 10, securing that you will receive continued support from Microsoft, 64-bit computing capabilities, and the peace of mind that comes with working in a more secure lab environment.
As your laboratory moves on to Windows 10, you will be required to purchase new acquisition PCs for instrument control. Since we do not want your computer to hold you back, SCIEX has created a solution for a seamless upgrade, the new SCIEX Alpha Workstation 2020 has just launched. Find out more about the benefits of getting up to speed with an upgrade to Windows 10 and to take advantage of our special upgrade programs.
Upgrading Analyst® Software for Compatibility with Windows 10 As always, our roadmap is completely defined by building the best product we can for you. Contact us anytime, if you have questions about the Windows 10 upgrade path or want to learn how to increase your lab’s productivity with our Windows 10 compatible software suite.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network